Pfizer Depo-Provera “Black Box” Urges Short-Term Use Only Due To Bone Loss
Executive Summary
A "black box" warning added to Pfizer's contraceptive injection Depo-Provera (medroxyprogesterone) states the drug should be treated as second-line for long-term use due to the potential for bone loss
You may also be interested in...
Mifeprex Labeling Change: “Routine” Response To Adverse Events, FDA Says
FDA's decision to strengthen warnings on Danco's Mifeprex (mifepristone) is not a signal that the agency will move to pull the product off the market, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, said Nov. 16
Mifeprex Labeling Change: “Routine” Response To Adverse Events, FDA Says
FDA's decision to strengthen warnings on Danco's Mifeprex (mifepristone) is not a signal that the agency will move to pull the product off the market, Center for Drug Evaluation & Research Acting Director Steven Galson, MD, said Nov. 16
Lunelle Class I Recall: Pharmacia To Provide Pregnancy Kits To Patients
Pharmacia's Class I recall of Lunelle pre-filled syringes is prompting the firm to provide pregnancy kits and alternative barrier contraception to patients who have received the monthly injection since January